Moccetti T, Rezzonico M, Clara F, Riva A, Tanzi F, Genoni M, Malacrida R
Clinica Medica Ospedale Civico Lugano.
Schweiz Med Wochenschr. 1988 Nov 19;118(46):1702-5.
With a small group of Swiss hospitals we had an opportunity of participating in ISIS-2, the major study on thrombolysis in acute myocardial infarction. Experience with our microcosm (Ospedale Civico Lugano) was compared with the macrocosm of the results of ISIS-2 in 17,187 randomized patients (in brackets). Mortality was 5.1% (7.8%) in our streptokinase group and 15.8% (12.8%) in our placebo group. In the ISIS-2 study the combination of thrombolytic therapy with streptokinase, and of antiplatelet therapy with aspirin, showed a reduction of approximately one third in acute mortality of myocardial infarction, stroke and reinfarction. Our experience confirms the reduced incidence of allergic side effects (3.5%), major bleeding (0.3%) and minor bleeding (2.9%) during or after thrombolytic therapy.
我们与一小部分瑞士医院共同参与了ISIS - 2研究，这是一项关于急性心肌梗死溶栓治疗的重要研究。我们将卢加诺市民医院的微观经验与ISIS - 2研究中17187名随机分组患者（括号内）的宏观结果进行了比较。我们的链激酶治疗组死亡率为5.1%（7.8%），安慰剂组死亡率为15.8%（12.8%）。在ISIS - 2研究中，链激酶溶栓治疗与阿司匹林抗血小板治疗相结合，使心肌梗死、中风和再梗死的急性死亡率降低了约三分之一。我们的经验证实，溶栓治疗期间或之后，过敏副作用（3.5%）、严重出血（0.3%）和轻微出血（2.9%）的发生率有所降低。
